Postoperative Acute Kidney Injury After Transcatheter Aortic Valve Replacement

Transcatheter aortic valve replacement (TAVR) has quickly become one of the common structural heart procedures performed in the last decades. TAVR has become even more popularized since the advent of PARTNER3 Trial in 2019. The multicenter, randomized study concluded that for patients with severe aortic stenosis who were at low surgical risk, the rate of the composite of death, stroke, or rehospitalization at 1 year was significantly lower with TAVR than with surgical aortic valve replacement (SAVR) [1]. While TAVRs have significantly improved morbidity and mortality in patients compared to SAVR [2], TAVR is not without complications. Acute kidney injury (AKI) after TAVR is not uncommon and is associated with increased morbidity and mortality. This literature review aims to summarize the current knowledge on AKI after TAVR and the associated risk factors, incidence, pathogenesis, and perioperative management strategies. AKI in this literature review for the intent of standardization is defined per VARC criteria, unless otherwise mentioned [3]. Briefly, this criterion utilizes the current definition of AKI which has been adopted by the majority of the nephrology community, including the KDIGO (Kidney Disease: Improving Global Outcomes) initiative [4].

Post-TAVR AKI is unfortunately a common complication, occurring in 1 out of 6 patients undergoing TAVR [5•]. It is also a complication that often lends itself to higher rates of overall mortality comparatively to non-AKI patients (15.9% vs. 0.8%; p < 0.01⁵). In addition, the length of stay is prolonged as well as the associated costs with the visit because of post-TAVR AKI. The incidence of post-TAVR AKI has varying degrees of reporting. The published rates of post-TAVR AKI typically vary from 10 to 30% depending on AKI criteria and/or definition as well as cited literature [6]. Furthermore, patients selected for TAVR often tend to be older and have a higher prevalence of preexisting chronic kidney disease (CKD), compared with SAVR cases [7]. Post-TAVR AKI is further risk stratified as the procedure often requires contrast administration. Other factors include the disruption of existing atherosclerotic plaque that is being manipulated during instrumentation of the procedure, producing increased risk and likelihood of both atheroembolic events, another well-known risk factor for post-TAVR AKI.

The pathophysiology for post-TAVR AKI patients is most likely multifactorial as there are multiple etiologies that are to be considered when evaluating the pathophysiology driving AKI in this setting. For example, age is an important factor to consider given that most patients who are receiving TAVRs tend to be older. By the age of 70, the kidneys have lost between 30 and 50% of their cortical glomeruli due to ischemic changes, and of the remaining glomeruli, most have some degree of sclerosis, as well as concomitant tubular and vascular changes leading to functional changes including reduction of renal blood flow of up to 50% from the age of 20 to 80 [8, 9]. To exemplify this point, patients who have existing CKD have an exponentially higher odds ratio of developing AKI. For patients with CKD 4–5 (eGFR < 30 ml/min/1.73 m²) and CKD 3b-5 (eGFR < 45 ml/min/1.73 m²), the odds ratio of developing AKI was 2.9 (CI 2.4–3.7) and 1.45 (CI: 1.28–1.7), respectively. This interplay is clinically significant because the hazard ratio for all cause death for this same cohort 1 year later was 2.0 (1.38–2.89) and 1.44 (1.04–1.98), respectively [1]. AKI is not without predisposing risk factors. While measures are performed in the preoperative risk assessment including AKI in the calculation for the European System for Cardiac Operative Risk Evaluation (EuroSCORE) I/II or the Society of Thoracic Surgeons (STS) Score. To parse these risks, the risk factors will be divided into pre/peri/postprocedural categories and further stratify into modifiable vs. non-modifiable risk factors. This review aims to summarize post-TAVR AKI incidence, modifiable risk factors, and considerations that have been published in the literature in recent years (2015 to 2023) (Table 1).

Preprocedural risk factors include age, history of CKD, diabetes mellitus, heart failure, atherosclerotic burden, fluid status, nephrotoxic agents, and global surgical risk [7]. Despite exclusion of patients with ESRD from pivotal TAVR trials, data shows that over 50% of high-risk patients suffer > 3a CKD and about 10% of them suffer > 4 CKD, with the risk of AKI increasing significantly at each stage of CKD advancement [10]. Of 7112 cases performed between 2016 and 2019, AKI occurred in 629 (8.8%). In-hospital AKI was significantly associated with the risk of 1-year mortality. Additionally, by evaluating the ratio of contrast volume to baseline estimated glomerular filtration rate (CV/eGFR), CV/eGFR > 2 and CV/eGFR > 3 were associated with AKI. There was also a correlation between the use of general anesthesia for TAVR and the risk of developing AKI [11]. While advanced imaging with fluoroscopy fusion images and TEE could potentially make contrast-free TAVR feasible, trends have shifted away from general anesthesia, thus limiting the use of procedural TEE in some settings [12]. Patients who present for TAVR with known reduced renal function are at great risk given the strong predictor of long-term mortality post-TAVR. Additional studies have evaluated and found that existing atherosclerosis, especially renal artery stenosis, was a predictor of AKI in 19% who did develop AKI; although these studies have shown this association, larger population validation is needed. Furthermore, risk factors such as heart failure and peripheral vascular disease are independent risk factors associated with AKI post-TAVR [13•].

Intraprocedural risk factors include approach route, moderate paravalvular aortic regurgitation, renal embolization, rapid ventricular pacing, exposure to contrast media, bleeding complications, duration of hemodynamic instability, hypotension, blood transfusion, or conversion to open surgery [14]. Study has shown that patients who underwent TAVR via transfemoral (TF) approach compared to those who had transapical (TA) or transaortic (TaO) approach had significantly less AKI post-TAVR. Another meta-analysis further supported this finding, showing across thirteen studies, the risk of AKI is 57% less likely to occur in TF-TAVR approach compared with non-TF approaches [15]. This highlights that non-TF approaches are more invasive, more time consuming, and contribute to intraoperative hemodynamic instability that negatively impacts renal function and can ultimately lead to post-TAVR AKI. This is also compounded by general findings that non-TF approaches are generally at higher risk for blood transfusion that may help explain the multifocal etiology regarding increased AKI risk post-TAVR. Lastly, TA and TaO approaches generally require general anesthesia and as opposed to MAC, which could further contribute to hemodynamic instability and increase duration of the procedure. Patients undergoing general anesthesia compared to monitored anesthetic care have shown no significant difference in 30 day mortality in some meta-analyses but there is some evidence in smaller studies, showing that general anesthesia as an independent risk factor for the development of post-TAVR AKI [16]. This can potentially result in an increase of the patient’s risk of post-TAVR AKI; however, further studies are needed to stratify general anesthesia as an independent risk factor for post-TAVR AKI.

Postprocedural risk factors include hemodynamic instability, postoperative bleeding, postoperative aortic insufficiency (AI) and/or paravalvular leak, anemia, and decreased left ventricular ejection fraction. While it is difficult to find existing literature to explicitly categorize postoperative blood transfusions, in patients who developed post-TAVR AKI, 55% of them had received packed red blood cells (pRBCs) transfusion, while only 21% of the patients who did not receive pRBCs develop post-TAVR AKI (p = 0.002) [17•]. To address hemodynamic instability, it is well understood that renal perfusion is highly dependent on cardiac output, and therefore, it is reasonable to deduce that prolonged postoperative hemodynamic instability can result in post-TAVR AKI. It is not well appreciated in the current literature the degree to which post-TAVR hypotension, vasopressors, and inotropes directly contribute to the pathogenesis of post-TAVR AKI. Thus, further prospective studies are warranted to further explore these findings. Highlighting other postprocedural risk factors, one study noted that postoperative inotropes and vasopressors use was independently associated with the development of post-TAVR AKI, with the caveat that concurrent intraoperative inotropes and vasopressors administered were not associated with the development of post-TAVR AKI. These findings suggest further prospective studies are needed to further stratify the degree of impact inotropes and vasopressors on post-TAVR AKI in the perioperative period. Post-TAVR AKI has been shown in multiple studies that it is an independent risk factor for increased short-term and long-term mortality [18]. Multiple factors must be accounted for when evaluating a patient’s total risk assessment in the setting of known or precipitated AKI in the perioperative period. In addition, it must be recognized that while no intervention is without risks, risk factors can be stratified into modifiable and non-modifiable risk factors (Table 2).

Post-TAVR AKI can be mitigated when the TF-TAVR approach is implemented compared to non-TF approaches. Additionally, patients with preexisting CKD have markedly increased morbidity and mortality when undergoing TAVR. Moreover, patients who require blood products intraoperatively in the setting of hemodynamic instability potentiates post-TAVR AKI risk. Currently, there is no consensus on fluid management in the perioperative setting; thus, future studies are warranted to help provide further guidance. Given that TAVR is continuously expanding its eligible patient population, opportunities remain to continue to optimize and potentially standardize delivery of care to further prevent post-TAVR AKI and ultimately improve peri-procedural outcomes.